CCO Independent Conference Highlights of the European Hematology Association 2022 Congress
  • CME

June 9-17, 2022; Vienna, Austria
Review expert perspectives and insights on the most clinically important data presented at EHA 2022 for acute myeloid leukemia, chronic lymphocytic leukemia, follicular lymphoma, multiple myeloma, and Waldenström macroglobulinemia.
Stéphane de Botton, MD
Jesus San-Miguel, MD, PhD
Alessandra Tedeschi, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: September 6, 2022 Expiration: September 5, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate clinical trial data for hematologic malignancies and determine how they have an impact on evolving global clinical practice patterns, as well as how these data can be applied to personalize care and optimize patient outcomes
  • Assess the mechanisms of action of novel investigational agents being examined in patients with hematologic malignancies, including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms
  • Develop strategies to address treatment-related adverse events in patients who receive therapy for hematologic malignancies

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Jazz Pharmaceuticals, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Stéphane de Botton, MD

Associate Professor
Department of Clinical Hematology
Université Paris Saclay
Paris, France
Physician
Department of Hematology
Gustave Roussy
Villejuif, France

Stéphane De Botton, MD: consultant/advisor/speaker: AbbVie, Astellas, Bristol-Myers Squibb, Forma, Jazz, Servier, Syros.
Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Clinica Universidad de Navarra
Universidad de Navarra
Pamplona, Spain

Jesús F. San-Miguel, MD, PhD:consultant: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, MSD, Novartis, Regeneron, Roche, SecuraBio, Sanofi, Takeda.
Alessandra Tedeschi, MD

Director of Indolent Lymphoproliferative Disorders
Department of Hematology
Niguarda Cancer Center
Niguarda Hospital
Milan, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Janssen.

Staff

Kristen Rosenthal, PhD

Associate Director, Scientific Services

Kristen Rosenthal, PhD, has no relevant financial relationships to disclose.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant financial relationships to disclose.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Justine Stanley

Editorial Contributor

Justine Stanley has no relevant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer: individual publicly traded stocks/stock options: AstraZeneca.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with hematologic malignancies.

Goal

The goal of this activity is to improve global learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with hematologic malignancies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 06, 2022, through September 05, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Learn from an infectious diseases specialist about important considerations when caring for a cancer patient with influenza, from Clinical Care Options (CCO)

Tracy Zivin-Tutela, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 8, 2022 Expired: December 7, 2023

Expert slides from Drs. Heather McArthur, Nadia Harbeck, and Komal Jhaveri, on HER2 testing, defining HER2-low status, and mastering the clinical use and safety profile of antibody-drug conjugates, from Clinical Care Options (CCO)

person default Nadia Harbeck, MD, PhD Komal Jhaveri, MD Heather McArthur, MD, MPH Released: December 8, 2022

Expert slides from Dr Melinda Telli on perioperative therapies for early triple-negative breast cancer (TNBC), from Clinical Care Options (CCO)

Melinda Telli, MD Released: December 7, 2022

Expert slides from Dr Tiffany Traina on perioperative therapies for high-risk HR+/HER2- early breast cancer, from Clinical Care Options (CCO)

Tiffany A. Traina, MD Released: December 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings